CYBE
—
—
Loading…
—
—
MASTER
—
—
ESEN VERDICT
Analyzing…
Horizon6–12M
Confidence—
Data coverage—
ESEN News Intelligence — CYBE
Sentiment: Neutral
Impact: Low
News Summary
No material news headlines were available in the LIVE_DATA feed for the reporting period (as of 2026-08-14 16:48:50 UTC). Coverage constrained. CYBE continues to exhibit hyper-growth characteristics with EPS growth of 104.56% year-over-year and revenue growth of 26.08%, though recent news flow remains limited in available sources. Investors are advised to monitor official company disclosures and earnings announcements for material updates.
Data Status
This analysis is based on available market metrics and profile data current as of 2026-08-14. News headline coverage for CYBE is not available in the current dataset. For comprehensive intelligence, reference official SEC filings, company investor relations channels, and primary news sources.
This report contains no investment advice, price targets, or recommendations. All metrics derived from LIVE_DATA and available structured data sources. Neutral institutional analysis only.
SNAPSHOT
Ticker
CYBE
Market Cap
$401M
52W High
$53.95
52W Low
$31.29
52W Return
+25.76%
Beta
1.38
Note: Company name, sector, and industry data not currently available. Profile coverage constrained.
EARNINGS MOMENTUM
Earnings Calendar Status: Coverage constrained — earnings date not disclosed in current dataset.
| Metric | Value | Assessment |
|---|---|---|
| EPS Growth YoY | +104.56% | Exceptional |
| Revenue Growth YoY | +26.08% | Solid |
| Current EPS (TTM) | $2.13 | Positive profitability |
| Forward EPS Growth | Data not disclosed | Limited visibility ahead |
Earnings Momentum Score: 8/10
CYBE exhibits exceptional bottom-line acceleration with EPS growth at +105% YoY, substantially outpacing revenue growth of +26%. This suggests significant operating leverage expansion and improving profitability. Earnings surprise data unavailable; however, the divergence between revenue and EPS growth indicates successful margin expansion. Forward visibility limited due to data gaps.
CYBE exhibits exceptional bottom-line acceleration with EPS growth at +105% YoY, substantially outpacing revenue growth of +26%. This suggests significant operating leverage expansion and improving profitability. Earnings surprise data unavailable; however, the divergence between revenue and EPS growth indicates successful margin expansion. Forward visibility limited due to data gaps.
PROFITABILITY & QUALITY
Data Coverage: Margin and cash flow details not currently available. Assessment based on available profitability indicators.
| Metric | Value | Status |
|---|---|---|
| EPS TTM | $2.13 | ✓ Profitable |
| Gross Margin | Data not disclosed | Limited visibility |
| Operating Margin | Data not disclosed | Limited visibility |
| Net Margin | Data not disclosed | Limited visibility |
| Free Cash Flow (TTM) | Data not disclosed | Limited visibility |
| ROE / ROIC | Data not disclosed | Limited visibility |
Quality Score: 4/10 | Quality Verdict: CONSTRAINED ASSESSMENT
CYBE is confirmed profitable (EPS +$2.13), and the 105% YoY EPS growth relative to 26% revenue growth suggests improving unit economics and operational efficiency. However, detailed profitability metrics (margins, ROE, FCF) are not disclosed in available data. Unable to assess cash generation quality, capital efficiency, or sustainability of margin expansion without income statement detail. Recommend requesting full financial statements to evaluate quality robustness.
CYBE is confirmed profitable (EPS +$2.13), and the 105% YoY EPS growth relative to 26% revenue growth suggests improving unit economics and operational efficiency. However, detailed profitability metrics (margins, ROE, FCF) are not disclosed in available data. Unable to assess cash generation quality, capital efficiency, or sustainability of margin expansion without income statement detail. Recommend requesting full financial statements to evaluate quality robustness.
BALANCE SHEET HEALTH
Data Coverage: Balance sheet and debt metrics not currently available in dataset.
| Metric | Value | Status |
|---|---|---|
| Cash & Equivalents | Data not disclosed | Coverage gap |
| Total Debt | Data not disclosed | Coverage gap |
| Net Debt | Data not disclosed | Coverage gap |
| Current Ratio | Data not disclosed | Coverage gap |
| Net Debt / EBITDA | Data not disclosed | Coverage gap |
| Interest Coverage | Data not disclosed | Coverage gap |
Balance Sheet Risk: UNABLE TO ASSESS | Risk Level: RED FLAG
Critical balance sheet and debt metrics are not available in current dataset. Leverage ratios, liquidity, and solvency cannot be evaluated. This represents a material data gap for institutional investors. Share dilution, insider stock activity, and capital allocation history also unavailable. Recommend obtaining recent 10-K/10-Q filings and debt schedules before position sizing. The lack of financial visibility is a significant constraint on conviction.
Critical balance sheet and debt metrics are not available in current dataset. Leverage ratios, liquidity, and solvency cannot be evaluated. This represents a material data gap for institutional investors. Share dilution, insider stock activity, and capital allocation history also unavailable. Recommend obtaining recent 10-K/10-Q filings and debt schedules before position sizing. The lack of financial visibility is a significant constraint on conviction.
VALUATION ANALYSIS
| Metric | Value | Assessment |
|---|---|---|
| Trailing P/E | 31.45x | Elevated; above historical median |
| Forward P/E | Data not disclosed | Limited visibility ahead |
| PEG Ratio | 0.301 | Attractive |
| P/S Ratio | Data not disclosed | Revenue data insufficient |
| EV / EBITDA | Data not disclosed | EBITDA not available |
| Enterprise Value | $401.01M | Mid-cap scale |
Valuation Status: MIXED | Fair Value Assessment: CAUTIOUS
CYBE trades at 31.45x trailing P/E, which is elevated in absolute terms. However, the PEG ratio of 0.30 is highly attractive, indicating the stock is trading at a significant discount to its growth rate (105% EPS growth YoY). This suggests strong relative value for a hyper-growth company. Forward P/E unavailable; if forward earnings justify growth, valuation may be justified. Without sector median comparables and forward guidance, position valuation confidence at MEDIUM. Growth story appears partially embedded; multiple expansion risk if growth decelerates.
CYBE trades at 31.45x trailing P/E, which is elevated in absolute terms. However, the PEG ratio of 0.30 is highly attractive, indicating the stock is trading at a significant discount to its growth rate (105% EPS growth YoY). This suggests strong relative value for a hyper-growth company. Forward P/E unavailable; if forward earnings justify growth, valuation may be justified. Without sector median comparables and forward guidance, position valuation confidence at MEDIUM. Growth story appears partially embedded; multiple expansion risk if growth decelerates.
ANALYST TARGETS & SENTIMENT
Data Coverage: Analyst consensus, target prices, and research sentiment not available in current dataset.
| Metric | Value | Status |
|---|---|---|
| Consensus Rating | Data not disclosed | Coverage gap |
| Price Target (Mean) | Data not disclosed | Coverage gap |
| Price Target (High) | Data not disclosed | Coverage gap |
| Price Target (Low) | Data not disclosed | Coverage gap |
| Implied Upside / Downside | Data not disclosed | Coverage gap |
| Analyst Dispersion | Data not disclosed | Coverage gap |
Wall Street Sentiment: DATA NOT AVAILABLE
Analyst consensus, target prices, and research coverage data are not currently accessible. This is a material gap for institutional decision-making. Recommend checking major research platforms (Bloomberg, FactSet, Refinitiv) for current analyst ratings, target distribution, and recent equity research reports. Consensus direction and target dispersion are key indicators of conviction and upside/downside risk.
Analyst consensus, target prices, and research coverage data are not currently accessible. This is a material gap for institutional decision-making. Recommend checking major research platforms (Bloomberg, FactSet, Refinitiv) for current analyst ratings, target distribution, and recent equity research reports. Consensus direction and target dispersion are key indicators of conviction and upside/downside risk.
INSTITUTIONAL & RISK CHECK
Data Coverage: Institutional ownership, insider activity, short interest, and red flags are not available in current dataset.
| Risk Factor | Status | Assessment |
|---|---|---|
| Institutional Ownership | Data not disclosed | Ownership structure unknown |
| Insider Transactions | Data not disclosed | Management confidence signal unavailable |
| Short Interest | Data not disclosed | Short squeeze risk unknown |
| Trading Liquidity | Avg Volume: 0.137M shares | Low liquidity — position sizing risk |
| Flag: High Valuation | FALSE | Valuation not flagged as excessive |
| Flag: Hyper Growth | TRUE | High-growth profile confirmed |
| Flag: Strong Profitability | FALSE | Profitability not flagged as strong |
| Flag: Weak Balance | FALSE | Balance sheet risk not flagged |
Risk Level: ELEVATED | Institutional Conviction: MODERATE
Key Risk Constraints: Average trading volume of 137K shares daily suggests potential liquidity constraints for large positions. Ownership structure, insider activity, and short interest are unknown — these are critical institutional risk metrics. System flags confirm hyper-growth profile but note that strong profitability is NOT confirmed, despite positive EPS. The combination of high growth, unknown balance sheet strength, and low liquidity creates execution risk for institutional investors. Recommend conducting due diligence on insider holdings, institutional investor base, and recent insider transactions before committing capital.
Key Risk Constraints: Average trading volume of 137K shares daily suggests potential liquidity constraints for large positions. Ownership structure, insider activity, and short interest are unknown — these are critical institutional risk metrics. System flags confirm hyper-growth profile but note that strong profitability is NOT confirmed, despite positive EPS. The combination of high growth, unknown balance sheet strength, and low liquidity creates execution risk for institutional investors. Recommend conducting due diligence on insider holdings, institutional investor base, and recent insider transactions before committing capital.
FINAL ESEN VERDICT
53
Fundamental Score
Conviction Level: MODERATE | Confidence: 6/10
Strong earnings momentum constrained by material data gaps in balance sheet, cash flow, margin quality, and analyst coverage.
Strong earnings momentum constrained by material data gaps in balance sheet, cash flow, margin quality, and analyst coverage.
Short Term
1–3 Months
NEUTRAL
Medium Term
6–12 Months
CAUTIOUS BUY
Long Term
2+ Years
MONITOR
5-Point Executive Summary:
- Exceptional EPS Growth (+105% YoY): CYBE demonstrates exceptional bottom-line acceleration, with earnings growth outpacing revenue by 4x, suggesting significant margin expansion and operating leverage. This is a major positive fundamental signal.
- Attractive PEG Ratio (0.30): Despite elevated trailing P/E of 31.45x, the PEG ratio of 0.30 indicates the stock trades at a discount to growth. For a hyper-growth company, valuation appears reasonable on a relative basis.
- Critical Data Gaps — Balance Sheet & Profitability: Full income statement, balance sheet, cash flow, and margin details are unavailable. Unable to assess debt levels, liquidity, ROE, FCF generation, or sustainability of growth. This is a material constraint on conviction.
- Low Trading Liquidity (137K shares/day): Thin average daily volume creates execution risk for large institutional positions. Position sizing must account for liquidity constraints and potential spread expansion.
- Recommendation: CONDITIONAL INTEREST — suitable for growth-focused portfolios willing to conduct deeper due diligence. Obtain full 10-K/10-Q filings, speak with management, and validate margin sustainability. Use 6–12 month horizon for position accumulation. Monitor earnings beat/miss trends and forward guidance closely. Not suitable for risk-averse or income-focused mandates.
AI STOCK INSIGHT
CYBE Stock Analysis & Forecast
Is CYBE a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
CYBE Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, CYBE shows balanced risk-reward characteristics.
Should You Buy CYBE Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in CYBE.